Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $10.01M |
| Net Income (Most Recent Fiscal Year) | $-337.71M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.65 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4341.53% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -44.17% |
| Return on Assets (Trailing 12 Months) | -39.53% |
| Current Ratio (Most Recent Fiscal Quarter) | 19.96 |
| Quick Ratio (Most Recent Fiscal Quarter) | 19.96 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.21 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.46 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.36 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 171.45M |
| Free Float | 163.10M |
| Market Capitalization | $474.90M |
| Average Volume (Last 20 Days) | 2.49M |
| Beta (Past 60 Months) | 1.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.87% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.98% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |